
Saudi Arabia Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging cente
Description
Saudi Arabia Radiopharmaceuticals Market By Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), By Application (Cancer, Cardiology, Others), By Type (Diagnostic, Therapeutic), By End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032
The Saudi Arabia radiopharmaceuticals market is projected to register a healthy CAGR during the forecast period. The market growth is attributed to increasing prevalence of cancer, opening of new diagnostic and treatment centers, and rising awareness on long-term health benefits of radiopharmaceuticals. Radiopharmaceuticals are used for the diagnosis and treatment of a wide range of diseases, such as cancer, cardiovascular diseases, and diabetes.
In Saudi Arabia, numerous government policies and public-private sector initiatives have been launched to strengthen the radiopharmaceuticals sector. These initiatives include increasing access to radiopharmaceuticals facilities and encouraging foreign direct investment in the medical and healthcare sector. The country is also taking efforts to promote local manufacturing and production of radiopharmaceuticals.
The Saudi Arabia radiopharmaceuticals market is driven by the increasing prevalence of cancer and the rising demand for imaging procedures. Moreover, the rising awareness about the long-term health benefits offered by diagnostic imaging and treatment technologies is driving the growth of the radiopharmaceuticals market in the country. Furthermore, increasing healthcare expenditure in the country is expected to boost the growth of the radiopharmaceuticals market in the upcoming years.
A rapid increase in the prevalence of chronic illness like cancer, cardiovascular disease, and neurology is a crucial factor driving the radiopharmaceuticals market expansion. The increase in prevalence of target disease and surge in the need for diagnosis and treatment boosts the demand for radiopharmaceuticals. Radiopharmaceuticals are radioactive drugs that are used to detect and treat cancer cells. They are administered into the body and accumulate in cancerous tissues, allowing for the diagnosis and treatment of the disease.
On the contrary, limited reimbursement policies and high cost of radiopharmaceuticals are some of the factors hampering the market growth. Moreover, lack of skilled personnel, low availability of radiopharmaceuticals, and long working hours for radiopharmaceutical technicians are some of the other restraints hampering the growth of the radiopharmaceuticals market. The Saudi Arabia radiopharmaceuticals market players are expected to witness several growth opportunities in the upcoming years. The increasing number of radiopharmaceutical manufacturing companies and rising new product launches are expected to boost the market growth during the forecast period. Moreover, increasing R&D activities in the field of nuclear medicine and radiopharmaceuticals is likely to create lucrative growth opportunities for the radiopharmaceuticals market players.
The government is also focusing on the improvement of the regulatory framework, which will open new possibilities for market players. Furthermore, rising initiatives for the promotion of radiopharmaceuticals and imaging technologies along with the development of healthcare infrastructure in the country are expected to boost the growth of the market in the upcoming years.
The Porter’s Five Forces Analysis of the Saudi Arabia radiopharmaceuticals market provides detailed insights into the competitive landscape of the market. It includes market competition from existing players, market entry barriers, threat of new entrants, bargaining power of suppliers and buyers, and threat of substitutes. The bargaining power of buyers and suppliers is high as the market is highly fragmented. Moreover, the presence of numerous regional and global players adds to the level of competition in the market. However, the presence of numerous barriers to entry limits the entry of new players in the market. The threat of substitutes is also high due to the availability of numerous alternatives to radiopharmaceuticals.
The SWOT analysis of the Saudi Arabia radiopharmaceuticals market does a detailed evaluation of the strengths, weaknesses, opportunities, and threats of the market. The market is supported by the increasing demand for imaging procedures and rising awareness about the long-term health benefits of radiopharmaceuticals. In addition, growing R&D activities along with the increasing number of radiopathology technicians in Saudi Arabia are also considered as the market growth driving factors. Lack of skilled personnel is one of the majors factors hampering the market growth.
The rising number of radiopharmaceutical manufacturing companies and new product launches are expected to create lucrative growth opportunities for the market players. In addition, rising initiatives for the promotion of radiopharmaceuticals and imaging technologies along with the development of healthcare infrastructure in the country is expected to drive the market growth. The Saudi Arabia radiopharmaceuticals market is expected to witness a considerable growth in the upcoming years due to increasing support from government bodies & healthcare providers and technological advancements in radiopharmaceutical production. Also, increasing investments in the medical sector are expected to encourage the use of radiopharmaceuticals. Government programs including the construction of nuclear medicine imaging and therapy facilities in major cities around the country are projected to boost the market expansion.
High cost of radiopharmaceuticals and limited reimbursement policies are projected to act as a restraining factors for the growth of the Saudi Arabia radiopharmaceuticals market. Market players are focusing on developing and launching new radiopharmaceuticals in this market. In 2018, a Saudi-based healthcare company, Al Amal, launched two new products, a Tc-99m-comprised radiopharmaceuticals and a cancer treatment radioisotope called Holmium-166. This led to an increase in the demand for radiopharmaceuticals in the Saudi Arabia radiopharmaceuticals market. SPIMACO is investing in R&D operation, to create and release cutting-edge of radiopharmaceutical market.
Jubilant Life Sciences, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Al-Azizia Panda United Company, National Oil Company (NOC), Saudi Chemical Company (SCC), Saudi Organics Industries, Saudi International Chemicals LTD (SICL), Saudi Arabian Petrochemical Company (Ibn Zahr), Al Fanar Pharmacy Company are some of the companies operating in te market.
Key Benefits For Stakeholders
Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
Analyze the key strategies adopted by major market players in the Saudi Arabia radiopharmaceuticals market.
Assess and rank the top factors that are expected to affect the growth of the Saudi Arabia radiopharmaceuticals market.
Top player positioning provides a clear understanding of the present position of market players.
Detailed analysis of the Saudi Arabia radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.
Identify key investment pockets for various offerings in the market.
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis
Key Market Segments
By Type
Diagnostic
Therapeutic
By End User
Hospitals and clinics
Medical Imaging centers
Others
By Radioisotope
Fluorine 18
Iodine I
Gallium 68
Others
Technetium 99m
By Application
Cancer
Cardiology
Others
Key Market Players
Jubilant Life Sciences
Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
Gulf Pharmaceutical Industries (Julphar)
Al-Azizia Panda United Company
National Oil Company (NOC)
Saudi Chemical Company (SCC)
Saudi Organics Industries
Saudi International Chemicals LTD (SICL)
Saudi Arabian Petrochemical Company (Ibn Zahr)
Al Fanar Pharmacy Company
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
71 Pages
- CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter’s Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. COVID-19 Impact Analysis on the market
- CHAPTER 4: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
- 4.1. Overview
- 4.1.1. Market Size and Forecast, By Radioisotope
- 4.2. Technetium 99m
- 4.3. Fluorine 18
- 4.4. Iodine I
- 4.5. Gallium 68
- 4.6. Others
- CHAPTER 5: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market Size and Forecast, By Application
- 5.2. Cancer
- 5.3. Cardiology
- 5.4. Others
- CHAPTER 6: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE
- 6.1. Overview
- 6.1.1. Market Size and Forecast, By Type
- 6.2. Diagnostic
- 6.3. Therapeutic
- CHAPTER 7: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market Size and Forecast, By End User
- 7.2. Hospitals and clinics
- 7.3. Medical Imaging centers
- 7.4. Others
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Jubilant Life Sciences
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO)
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Gulf Pharmaceutical Industries (Julphar)
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
- 9.4. Al-Azizia Panda United Company
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. National Oil Company (NOC)
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
- 9.6. Saudi Chemical Company (SCC)
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Saudi Organics Industries
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Saudi International Chemicals LTD (SICL)
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
- 9.9. Saudi Arabian Petrochemical Company (Ibn Zahr)
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
- 9.10. Al Fanar Pharmacy Company
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments
- LIST OF TABLES
- TABLE 01. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
- TABLE 02. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
- TABLE 03. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 04. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 05. JUBILANT LIFE SCIENCES: KEY EXECUTIVES
- TABLE 06. JUBILANT LIFE SCIENCES: COMPANY SNAPSHOT
- TABLE 07. JUBILANT LIFE SCIENCES: OPERATING SEGMENTS
- TABLE 08. JUBILANT LIFE SCIENCES: PRODUCT PORTFOLIO
- TABLE 09. JUBILANT LIFE SCIENCES: KEY STRATERGIES
- TABLE 10. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): KEY EXECUTIVES
- TABLE 11. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): COMPANY SNAPSHOT
- TABLE 12. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): OPERATING SEGMENTS
- TABLE 13. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): PRODUCT PORTFOLIO
- TABLE 14. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): KEY STRATERGIES
- TABLE 15. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): KEY EXECUTIVES
- TABLE 16. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): COMPANY SNAPSHOT
- TABLE 17. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): OPERATING SEGMENTS
- TABLE 18. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): PRODUCT PORTFOLIO
- TABLE 19. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): KEY STRATERGIES
- TABLE 20. AL-AZIZIA PANDA UNITED COMPANY: KEY EXECUTIVES
- TABLE 21. AL-AZIZIA PANDA UNITED COMPANY: COMPANY SNAPSHOT
- TABLE 22. AL-AZIZIA PANDA UNITED COMPANY: OPERATING SEGMENTS
- TABLE 23. AL-AZIZIA PANDA UNITED COMPANY: PRODUCT PORTFOLIO
- TABLE 24. AL-AZIZIA PANDA UNITED COMPANY: KEY STRATERGIES
- TABLE 25. NATIONAL OIL COMPANY (NOC): KEY EXECUTIVES
- TABLE 26. NATIONAL OIL COMPANY (NOC): COMPANY SNAPSHOT
- TABLE 27. NATIONAL OIL COMPANY (NOC): OPERATING SEGMENTS
- TABLE 28. NATIONAL OIL COMPANY (NOC): PRODUCT PORTFOLIO
- TABLE 29. NATIONAL OIL COMPANY (NOC): KEY STRATERGIES
- TABLE 30. SAUDI CHEMICAL COMPANY (SCC): KEY EXECUTIVES
- TABLE 31. SAUDI CHEMICAL COMPANY (SCC): COMPANY SNAPSHOT
- TABLE 32. SAUDI CHEMICAL COMPANY (SCC): OPERATING SEGMENTS
- TABLE 33. SAUDI CHEMICAL COMPANY (SCC): PRODUCT PORTFOLIO
- TABLE 34. SAUDI CHEMICAL COMPANY (SCC): KEY STRATERGIES
- TABLE 35. SAUDI ORGANICS INDUSTRIES: KEY EXECUTIVES
- TABLE 36. SAUDI ORGANICS INDUSTRIES: COMPANY SNAPSHOT
- TABLE 37. SAUDI ORGANICS INDUSTRIES: OPERATING SEGMENTS
- TABLE 38. SAUDI ORGANICS INDUSTRIES: PRODUCT PORTFOLIO
- TABLE 39. SAUDI ORGANICS INDUSTRIES: KEY STRATERGIES
- TABLE 40. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): KEY EXECUTIVES
- TABLE 41. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): COMPANY SNAPSHOT
- TABLE 42. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): OPERATING SEGMENTS
- TABLE 43. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): PRODUCT PORTFOLIO
- TABLE 44. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): KEY STRATERGIES
- TABLE 45. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): KEY EXECUTIVES
- TABLE 46. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): COMPANY SNAPSHOT
- TABLE 47. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): OPERATING SEGMENTS
- TABLE 48. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): PRODUCT PORTFOLIO
- TABLE 49. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): KEY STRATERGIES
- TABLE 50. AL FANAR PHARMACY COMPANY: KEY EXECUTIVES
- TABLE 51. AL FANAR PHARMACY COMPANY: COMPANY SNAPSHOT
- TABLE 52. AL FANAR PHARMACY COMPANY: OPERATING SEGMENTS
- TABLE 53. AL FANAR PHARMACY COMPANY: PRODUCT PORTFOLIO
- TABLE 54. AL FANAR PHARMACY COMPANY: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 01. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF SAUDI ARABIA RADIOPHARMACEUTICALS MARKET, 2022-2032
- FIGURE 03. TOP INVESTMENT POCKETS IN SAUDI ARABIA RADIOPHARMACEUTICALS MARKET (2023-2032)
- FIGURE 04. PORTER FIVE-1
- FIGURE 05. PORTER FIVE-2
- FIGURE 06. PORTER FIVE-3
- FIGURE 07. PORTER FIVE-4
- FIGURE 08. PORTER FIVE-5
- FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET
- FIGURE 10. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
- FIGURE 11. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
- FIGURE 12. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
- FIGURE 13. SAUDI ARABIA RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
- FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 18. COMPETITIVE DASHBOARD
- FIGURE 19. COMPETITIVE HEATMAP: SAUDI ARABIA RADIOPHARMACEUTICALS MARKET
- FIGURE 20. TOP PLAYER POSITIONING, 2022
- FIGURE 21. JUBILANT LIFE SCIENCES: NET SALES, 2020-2022* ($MILLION)
- FIGURE 22. JUBILANT LIFE SCIENCES: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 23. JUBILANT LIFE SCIENCES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 24. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): NET SALES, 2020-2022* ($MILLION)
- FIGURE 25. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 26. SAUDI PHARMACEUTICAL INDUSTRIES & MEDICAL APPLIANCES CORPORATION (SPIMACO): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 27. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): NET SALES, 2020-2022* ($MILLION)
- FIGURE 28. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 29. GULF PHARMACEUTICAL INDUSTRIES (JULPHAR): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 30. AL-AZIZIA PANDA UNITED COMPANY: NET SALES, 2020-2022* ($MILLION)
- FIGURE 31. AL-AZIZIA PANDA UNITED COMPANY: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 32. AL-AZIZIA PANDA UNITED COMPANY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 33. NATIONAL OIL COMPANY (NOC): NET SALES, 2020-2022* ($MILLION)
- FIGURE 34. NATIONAL OIL COMPANY (NOC): REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 35. NATIONAL OIL COMPANY (NOC): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 36. SAUDI CHEMICAL COMPANY (SCC): NET SALES, 2020-2022* ($MILLION)
- FIGURE 37. SAUDI CHEMICAL COMPANY (SCC): REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 38. SAUDI CHEMICAL COMPANY (SCC): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 39. SAUDI ORGANICS INDUSTRIES: NET SALES, 2020-2022* ($MILLION)
- FIGURE 40. SAUDI ORGANICS INDUSTRIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 41. SAUDI ORGANICS INDUSTRIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 42. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): NET SALES, 2020-2022* ($MILLION)
- FIGURE 43. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 44. SAUDI INTERNATIONAL CHEMICALS LTD (SICL): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 45. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): NET SALES, 2020-2022* ($MILLION)
- FIGURE 46. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 47. SAUDI ARABIAN PETROCHEMICAL COMPANY (IBN ZAHR): REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
- FIGURE 48. AL FANAR PHARMACY COMPANY: NET SALES, 2020-2022* ($MILLION)
- FIGURE 49. AL FANAR PHARMACY COMPANY: REVENUE SHARE, BY SEGMENT, 2022 (%)
- FIGURE 50. AL FANAR PHARMACY COMPANY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.